Advertisement

The Reemergence of Measles

  • C. L. Abad
  • N. SafdarEmail author
Skin, Soft Tissue, Bone and Joint Infectious Diseases (N Safdar, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Skin, Soft Tissue, Bone and Joint Infections

Abstract

Measles, or rubeola, is a highly infectious, acute viral illness of childhood that is considered eliminated in the USA but has reemerged in the past few years. Globally, an estimated 20 million cases of measles continue to occur, and it remains a leading cause of death among young children. It is rare in the USA and other first world countries, but numerous outbreaks have occurred in the USA recently, due to a combination of factors including poor vaccine coverage and importation of cases among travelers returning from endemic areas. The diagnosis of measles is usually made clinically, when an individual presents with a constellation of symptoms including cough, coryza, conjunctivitis, high fever, and an erythematous maculopapular rash in a cephalocaudal distribution. Complications are common and include otitis media, pneumonia, encephalitis, and rarely death. A measles vaccine is available in two doses and provides excellent protection against the disease. Despite this, vaccination coverage, especially among young adults, remains poor. Given its resurgence in the USA and other countries, interventions are urgently needed to address low vaccination rates and vaccine hesitancy. Measles awareness should also be a priority among young clinicians, who may have never seen a case or are not familiar with the disease.

Keywords

Acute viral illness Acute viral illness of childhood Measles Measles vaccine 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Nasia Safdar and Cybele Abad have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

References

  1. 1.
    Clemmons NS, Gastanaduy PA, Fiebelkorn AP, Redd SB, Wallace GS. Measles—United States, January 4–April 2, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:373–6.PubMedGoogle Scholar
  2. 2.
    Simons E, Ferrari M, Fricks J, et al. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. Lancet. 2012;379:2173–8.CrossRefPubMedGoogle Scholar
  3. 3.
    World Health Organization. Global measles and rubella strategic plan: 2012–2020. Geneva, 2012.Google Scholar
  4. 4.
    Katz SL, Hinman AR. Summary and conclusions: measles elimination meeting, 16–17 March 2000. J Infect Dis. 2004;189 Suppl 1:S43–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Plotkin SA OW, Offit PA, eds. Vaccines. 6th ed. Philadelphia: Elsevier, 2012; 2012.Google Scholar
  6. 6.
    Centers for Disease Control and Prevention. Measles (rubeola): for healthcare professionals. 2014. http://www.cdc.gov/measles/hcp/index.html.
  7. 7.
    World Health Organization (WHO) Regional Office for Europe. Guidelines for measles and rubella outbreak investigation and response in the WHO European Region. Copenhagen: WHO. 2013. Available from: http://www.euro.who.int/__data/assets/pdf_file/0003/217164/OutbreakGuidelines-updated.pdf.
  8. 8.
    European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report: Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Stockholm: ECDC. 2013. Available from: http://www.ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf.
  9. 9.
    Pegorie M, Shankar K, Welfare WS, et al. Measles outbreak in Greater Manchester, England, October 2012 to September 2013: epidemiology and control. Euro Surveill. 2014;19.Google Scholar
  10. 10.
    Mason WH. Measles. In: Kliegman RMBR, Jenson HB, Stanton BF, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia: Saunders; 2007. p. 1331–7.Google Scholar
  11. 11.
    United States Centers for Disease Control and Prevention. Measles. In: Atkinson W, editor. Epidemiology and prevention of vaccine-preventable diseases. 12th ed. Washington, DC: Public Health Foundation; 2011. p. 173–92.Google Scholar
  12. 12.
    Strebel PM. Measles vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia: Saunders-Elsevier; 2008. p. 353–98.Google Scholar
  13. 13.
    Hirai Y, Asahata S, Ainoda Y, Fujita T, Kawashima M, Totsuka K. Truncal rash in adult measles. Int J Infect Dis. 2014;20:80–1.CrossRefPubMedGoogle Scholar
  14. 14.
    WHO Expanded Programme on Immunization. Manual for the laboratory diagnosis of measles and rubella virus infection, 2nd ed. Geneva, World Health Organization, 2006 (http://www.who.int/immunization_monitoring/LabManualFinal.pdf).
  15. 15.
    Roberts GB, Bain AD. The pathology of measles. J Pathol Bacteriol. 1958;76:111–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Atabani SF, Byrnes AA, Jaye A, et al. Natural measles causes prolonged suppression of interleukin-12 production. J Infect Dis. 2001;184:1–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J Infect Dis. 1994;170 Suppl 1:S24–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Schneider-Schaulies S, ter Meulen V. Pathogenic aspects of measles virus infections. Arch Virol Suppl. 1999;15:139–58.PubMedGoogle Scholar
  19. 19.
    Strebel PM. Measles vaccine. In: Plotkin SAOW, Offit PA, editors. Vaccines. 5th ed. Philadelphia: Saunders-Elsevier; 2008. p. 353–98.Google Scholar
  20. 20.
    Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis. 2004;189 Suppl 1:S4–16.CrossRefPubMedGoogle Scholar
  21. 21.
    Crosse BA. Subcutaneous and mediastinal emphysema complication of measles. J Infect. 1989;19:190.CrossRefPubMedGoogle Scholar
  22. 22.
    Markowitz LE, Nieburg P. The burden of acute respiratory infection due to measles in developing countries and the potential impact of measles vaccine. Rev Infect Dis. 1991;13 Suppl 6:S555–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Sharma A. A rare complication of measles: subcutaneous and mediastinal emphysema. J Trop Med Hyg. 1993;96:169–71.PubMedGoogle Scholar
  24. 24.
    Johnson RT. Inflammatory and demyelinating diseases. In: Johnson RT, editor. Viral infections of the nervous system. 2nd ed. Philadelphia: Lippincott-Raven; 1998. p. 227–64.Google Scholar
  25. 25.
    Cohen N, Golik A, Blatt A, et al. Pancreatic enzyme elevation in measles. J Clin Gastroenterol. 1994;19:292–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Koster FT, Curlin GC, Aziz KM, Haque A. Synergistic impact of measles and diarrhoea on nutrition and mortality in Bangladesh. Bull World Health Organ. 1981;59:901–8.PubMedCentralPubMedGoogle Scholar
  27. 27.
    Morley DC. Measles in the developing world. Proc R Soc Med. 1974;67:1112–5.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Cherry JD. Measles. In: Feigin RD, Cherry JD, editors. Textbook of pediatric infectious diseases. 4th ed. Philadelphia: WB Saunders; 1988. p. 2054–74.Google Scholar
  29. 29.
    Sommer A. Xerophthalmia, keratomalacia and nutritional blindness. Int Ophthalmol. 1990;14:195–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Hudson JB, Weinstein L, Chang TW. Thrombocytopenic purpura in measles. J Pediatr. 1956;48:48–56.CrossRefPubMedGoogle Scholar
  31. 31.
    Gavish D, Kleinman Y, Morag A, Chajek-Shaul T. Hepatitis and jaundice associated with measles in young adults. An analysis of 65 cases. Arch Intern Med. 1983;143:674–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Leibovici L, Sharir T, Kalter-Leibovici O, Alpert G, Epstein LM. An outbreak of measles among young adults. Clinical and laboratory features in 461 patients. J Adolesc Health Care. 1988;9:203–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Casanova-Cardiel LJ, Hermida-Escobedo C. Measles in the young adult. Clinical features of 201 cases. Rev Investig Clin. 1994;46:93–8.Google Scholar
  34. 34.
    Wairagkar NS, Gandhi BV, Katrak SM, et al. Acute renal failure with neurological involvement in adults associated with measles virus isolation. Lancet. 1999;354:992–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Waggoner J, Deresinski S. Rare and emerging viral infection in the transplant population. In: Safdar A, editor. Principles and practice of transplant infectious diseases. Berlin: Springer Medizin; 2013.Google Scholar
  36. 36.
    Turner A, Jeyaratnam D, Haworth F, et al. Measles-associated encephalopathy in children with renal transplants. Am J Transplant. 2006;6:1459–65.CrossRefPubMedGoogle Scholar
  37. 37.
    Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992;267:1237–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Krasinski K, Borkowsky W. Measles and measles immunity in children infected with human immunodeficiency virus. JAMA. 1989;261:2512–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Nadel S, McGann K, Hodinka RL, Rutstein R, Chatten J. Measles giant cell pneumonia in a child with human immunodeficiency virus infection. Pediatr Infect Dis J. 1991;10:542–4.CrossRefPubMedGoogle Scholar
  40. 40.
    Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1992;11:1008–14.CrossRefPubMedGoogle Scholar
  41. 41.
    Rudy BJ, Rutstein RM, Pinto-Martin J. Responses to measles immunization in children infected with human immunodeficiency virus. J Pediatr. 1994;125:72–4.CrossRefPubMedGoogle Scholar
  42. 42.
    Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis. 1994;19:454–62.CrossRefPubMedGoogle Scholar
  43. 43.
    Ross LA, Kim KS, Mason Jr WH, Gomperts E. Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am J Med. 1990;88:313–4.CrossRefPubMedGoogle Scholar
  44. 44.
    Stogner SW, King JW, Black-Payne C, Bocchini J. Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South Med J. 1993;86:1415–8.CrossRefPubMedGoogle Scholar
  45. 45.
    WHO guidelines for epidemic preparedness and response to measles outbreaks. 1999. Accessed 1 June 2015, at http://www.who.int/csr/resources/publications/measles/WHO_CDS_CSR_ISR_99_1/en/.
  46. 46.
    Moss WJ, Griffin DE. Measles. Lancet. 2012;379:153–64.CrossRefPubMedGoogle Scholar
  47. 47.
    Bloch AB, Orenstein WA, Stetler HC, et al. Health impact of measles vaccination in the United States. Pediatrics. 1985;76:524–32.PubMedGoogle Scholar
  48. 48.
    Hinman AR, Brandling-Bennett AD, Nieburg PI. The opportunity and obligation to eliminate measles from the United States. JAMA. 1979;242:1157–62.CrossRefPubMedGoogle Scholar
  49. 49.
    Hinman AR, Orenstein WA, Papania MJ. Evolution of measles elimination strategies in the United States. J Infect Dis. 2004;189 Suppl 1:S17–22.CrossRefPubMedGoogle Scholar
  50. 50.
    McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1–34.PubMedGoogle Scholar
  51. 51.
    Measles prevention. MMWR Morb Mortal Wkly Rep 1989;38 Suppl 9:1–18.Google Scholar
  52. 52.
    De Serres G, Boulianne N, Defay F, et al. Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12–14 months versus 15 months of age. Clin Infect Dis. 2012;55:394–402.CrossRefPubMedGoogle Scholar
  53. 53.
    Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measles-containing vaccines: a review of published literature. J Infect Dis. 2011;204 Suppl 1:S133–48.CrossRefPubMedGoogle Scholar
  54. 54.
    De Serres G, Boulianne N, Meyer F, Ward BJ. Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months. Epidemiol Infect. 1995;115:315–23.PubMedCentralCrossRefPubMedGoogle Scholar
  55. 55.
    Sutcliffe PA, Rea E. Outbreak of measles in a highly vaccinated secondary school population. CMAJ. 1996;155:1407–13.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Vitek CR, Aduddell M, Brinton MJ, Hoffman RE, Redd SC. Increased protections during a measles outbreak of children previously vaccinated with a second dose of measles-mumps-rubella vaccine. Pediatr Infect Dis J. 1999;18:620–3.CrossRefPubMedGoogle Scholar
  57. 57.
    Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics. 2005;116:1287–91.CrossRefPubMedGoogle Scholar
  58. 58.
    Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J. 1990;9:101–10.CrossRefPubMedGoogle Scholar
  59. 59.
    Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197:950–6.CrossRefPubMedGoogle Scholar
  60. 60.
    LeBaron CW, Beeler J, Sullivan BJ, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med. 2007;161:294–301.CrossRefPubMedGoogle Scholar
  61. 61.
    Markowitz LE, Albrecht P, Orenstein WA, Lett SM, Pugliese TJ, Farrell D. Persistence of measles antibody after revaccination. J Infect Dis. 1992;166:205–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis. 1995;172:1591–5.CrossRefPubMedGoogle Scholar
  63. 63.
    Fernandez-de Castro J, Kumate-Rodriguez J, Sepulveda J, Ramirez-Isunza JM, Valdespino-Gomez JL. Measles vaccination by the aerosol method in Mexico. Salud Publica Mex. 1997;39:53–60.CrossRefPubMedGoogle Scholar
  64. 64.
    Low N, Bavdekar A, Jeyaseelan L, et al. A randomized, controlled trial of an aerosolized vaccine against measles. N Engl J Med. 2015;372:1519–29.CrossRefPubMedGoogle Scholar
  65. 65.
    Dos Santos BA, Ranieri TS, Bercini M, et al. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Rev Panam Salud Publica. 2002;12:240–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Gatchalian S, Cordero-Yap L, Lu-Fong M, et al. A randomized comparative trial in order to assess the reactogenicity and immunogenicity of a new measles mumps rubella (MMR) vaccine when given as a first dose at 12–24 months of age. Southeast Asian J Trop Med Public Health. 1999;30:511–7.PubMedGoogle Scholar
  67. 67.
    Grillner L, Hedstrom CE, Bergstrom H, Forssman L, Rigner A, Lycke E. Vaccination against rubella of newly delivered women. Scand J Infect Dis. 1973;5:237–41.CrossRefPubMedGoogle Scholar
  68. 68.
    Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet. 1986;1:939–42.CrossRefPubMedGoogle Scholar
  69. 69.
    Weibel RE, Carlson Jr AJ, Villarejos VM, Buynak EB, McLean AA, Hilleman MR. Clinical and laboratory studies of combined live measles, mumps, and rubella vaccines using the RA 27/3 rubella virus. Proc Soc Exp Biol Med. 1980;165:323–6.CrossRefPubMedGoogle Scholar
  70. 70.
    Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst Rev. 2012;2, CD004407.PubMedGoogle Scholar
  71. 71.
    Evidence concerning rubella vaccines and arthritis, radiculoneuritis, and thrombocytopenic purpura. Adverse effects of pertussis and rubella vaccines: a report of the Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. In: Howson CP, Howe CJ, HVF, editors. Institute of Medicine. Washington, DC: National Academy Press; 1991:187–205.Google Scholar
  72. 72.
    Measles and mumps vaccines. Adverse events associated with childhood vaccines evidence bearing on causality. In: Stratton KR, Howe CJ, Johnston RBJ, editors. Institute of Medicine. Washington, DC: National Academy Press; 1994:118–86.Google Scholar
  73. 73.
    Immunization safety review: measles-mumps-rubella vaccine and autism. In: Stratton K, Gable A, Shetty P, M M, editors. Institute of Medicine. Washington, DC: National Academy Press; 2001.Google Scholar
  74. 74.
    Immunization safety review: vaccines and autism Institute of Medicine. Washington, DC: National Academy Press; 2004.Google Scholar
  75. 75.
    Measles, mumps, and rubella vaccine. Adverse effects of vaccines: evidence and causality Institute of Medicine Washington, DC; The National Academies Press; 2012.Google Scholar
  76. 76.
    Taylor B, Miller E, Lingam R, Andrews N, Simmons A, Stowe J. Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study. BMJ. 2002;324:393–6.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637–41.CrossRefPubMedGoogle Scholar
  78. 78.
    Madsen KM, Hviid A, Vestergaard M, et al. A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med. 2002;347:1477–82.CrossRefPubMedGoogle Scholar
  79. 79.
    Daley DJ, Gani J. Epidemic modelling: an introduction Cambridge. United Kingdom: Cambridge University Press; 1999.Google Scholar
  80. 80.
    Orenstein W, Seib K. Mounting a good offense against measles. N Engl J Med. 2014;371:1661–3.CrossRefPubMedGoogle Scholar
  81. 81.
    DeStefano F. Vaccines and autism: evidence does not support a causal association. Clin Pharmacol Ther. 2007;82:756–9.CrossRefPubMedGoogle Scholar
  82. 82.
    Doja A, Roberts W. Immunizations and autism: a review of the literature. Can J Neurol Sci. 2006;33:341–6.CrossRefPubMedGoogle Scholar
  83. 83.
    Fombonne E. Are measles infections or measles immunizations linked to autism? J Autism Dev Disord. 1999;29:349–50.CrossRefPubMedGoogle Scholar
  84. 84.
    Fombonne E, Cook EH. MMR and autistic enterocolitis: consistent epidemiological failure to find an association. Mol Psychiatry. 2003;8:133–4.CrossRefPubMedGoogle Scholar
  85. 85.
    Offit PA. Vaccines and autism revisited—the Hannah Poling case. N Engl J Med. 2008;358:2089–91.CrossRefPubMedGoogle Scholar
  86. 86.
    Smith MJ, Ellenberg SS, Bell LM, Rubin DM. Media coverage of the measles-mumps-rubella vaccine and autism controversy and its relationship to MMR immunization rates in the United States. Pediatrics. 2008;121:e836–43.CrossRefPubMedGoogle Scholar
  87. 87.
    Feikin DR, Lezotte DC, Hamman RF, Salmon DA, Chen RT, Hoffman RE. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA. 2000;284:3145–50.CrossRefPubMedGoogle Scholar
  88. 88.
    Salmon DA, Haber M, Gangarosa EJ, Phillips L, Smith NJ, Chen RT. Health consequences of religious and philosophical exemptions from immunization laws: individual and societal risk of measles. JAMA. 1999;282:47–53.CrossRefPubMedGoogle Scholar
  89. 89.
    Omer SB, Enger KS, Moulton LH, Halsey NA, Stokley S, Salmon DA. Geographic clustering of nonmedical exemptions to school immunization requirements and associations with geographic clustering of pertussis. Am J Epidemiol. 2008;168:1389–96.CrossRefPubMedGoogle Scholar
  90. 90.
    Zipprich J, Winter K, Hacker J, Xia D, Watt J, Harriman K. Measles outbreak—California, December 2014-February 2015. MMWR Morb Mortal Wkly Rep. 2015;64:153–4.PubMedGoogle Scholar
  91. 91.
    Carrillo-Santisteve P, Lopalco PL. Measles still spreads in Europe: who is responsible for the failure to vaccinate? Clin Microbiol Infect. 2012;18 Suppl 5:50–6.CrossRefPubMedGoogle Scholar
  92. 92.
    Kata A. Anti-vaccine activists, Web 2.0, and the postmodern paradigm—an overview of tactics and tropes used online by the anti-vaccination movement. Vaccine. 2012;30:3778–89.CrossRefPubMedGoogle Scholar
  93. 93.
    Salmon DA, Moulton LH, Omer SB, DeHart MP, Stokley S, Halsey NA. Factors associated with refusal of childhood vaccines among parents of school-aged children: a case–control study. Arch Pediatr Adolesc Med. 2005;159:470–6.CrossRefPubMedGoogle Scholar
  94. 94.
    Flanagan-Klygis EA, Sharp L, Frader JE. Dismissing the family who refuses vaccines: a study of pediatrician attitudes. Arch Pediatr Adolesc Med. 2005;159:929–34.CrossRefPubMedGoogle Scholar
  95. 95.
    Freed GL, Clark SJ, Hibbs BF, Santoli JM. Parental vaccine safety concerns. The experiences of pediatricians and family physicians. Am J Prev Med. 2004;26:11–4.CrossRefPubMedGoogle Scholar
  96. 96.
    Diekema DS. Responding to parental refusals of immunization of children. Pediatrics. 2005;115:1428–31.CrossRefPubMedGoogle Scholar
  97. 97.
    Salmon DA, Pan WK, Omer SB, et al. Vaccine knowledge and practices of primary care providers of exempt vs. vaccinated children. Hum Vaccin. 2008;4:286–91.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of MedicineUniversity of the Philippines-Philippine General Hospital, Manila/The Medical CityPasig CityPhilippines
  2. 2.William S. Middleton Memorial Veterans Hospital and the Department of MedicineUniversity of Wisconsin-Madison School of MedicineMadisonUSA

Personalised recommendations